Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. The amount of risk involved ranges from fair to great, should a study come back negative or a candidate not be approved. Conversely, if a drug is approved or passes a clinical trial, there can be massive upside.
In simpler terms, these updates within the industry have the potential to make or break biopharma companies.
Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in February. We have added some color, a recent trading history and a consensus analyst price target.
It��s worth mentioning that these dates may be subject to change due to various internal and outside factors. Some of these changes are positive developments and some can be disasters if a company is deeply financed.
As a side note about the Prescription Drug User Fee Act (PDUFA): a Priority Review designation is granted to medicines that the FDA determines have the potential to provide significant improvements in the treatment, prevention or diagnosis of a disease.
Best Biotech Stocks To Invest In 2019: On Assignment Inc.(ASGN)
Advisors' Opinion:- [By Logan Wallace]
Insperity (NYSE: NSP) and ASGN (NYSE:ASGN) are both mid-cap business services companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.
- [By Joseph Griffin]
ASGN (NYSE: ASGN) and Amn Healthcare Services (NYSE:AMN) are both mid-cap computer and technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.
Best Biotech Stocks To Invest In 2019: First Connecticut Bancorp, Inc.(FBNK)
Advisors' Opinion:- [By Max Byerly]
BidaskClub downgraded shares of First Connecticut Bancorp (NASDAQ:FBNK) from a hold rating to a sell rating in a research note issued to investors on Wednesday morning.
- [By Logan Wallace]
First Connecticut Bancorp (NASDAQ: FBNK) and Berkshire Hills Bancorp (NYSE:BHLB) are both small-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.
- [By Joseph Griffin]
Southern Missouri Bancorp (NASDAQ: SMBC) and First Connecticut Bancorp (NASDAQ:FBNK) are both small-cap finance companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.
- [By Ethan Ryder]
First Connecticut Bancorp (NASDAQ: FBNK) and Entegra Financial (NASDAQ:ENFC) are both small-cap finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, analyst recommendations, institutional ownership and risk.
- [By Jordan Wathen]
Shares of First Connecticut Bancorp Inc. (NASDAQ:FBNK) are soaring today, rising by more than 19% as of 11:00 a.m. EDT on news of an acquisition. The parent company of�Farmington Bank will be acquired by People's United Financial (NASDAQ:PBCT) in an all-stock transaction valued at $544 million.
- [By Logan Wallace]
Get a free copy of the Zacks research report on First Connecticut Bancorp (FBNK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Best Biotech Stocks To Invest In 2019: Qiagen N.V.(QGEN)
Advisors' Opinion:- [By Brian Orelli]
Qiagen (NYSE:QGEN), the molecular testing and lab supply company, started the year off with growth at the low end of its yearly guidance,�although the first-quarter sales number was in line with where management expected to start the year.
- [By Joseph Griffin]
Qiagen (NYSE: QGEN) is one of 91 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Qiagen to related companies based on the strength of its valuation, profitability, risk, dividends, analyst recommendations, institutional ownership and earnings.
- [By Ethan Ryder]
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
Get Coty alerts: Accused Bigamist from San Angelo is On the Run Again (sanangelolive.com) Cosmetics Manufacturer Coty Takes Retail Space in Times Square (commercialobserver.com) Analyzing Colgate-Palmolive (CL) and Coty (COTY) (americanbankingnews.com) 3 Movers of Yesterday- Coty Inc. (NYSE:COTY), Alphabet Inc. (NASDAQ:GOOG), QIAGEN NV (NYSE:QGEN) (journalfinance.net) Trending Hot Stock’s Analysis �� Coty Inc. (NYSE:COTY) (nasdaqjournal.com)A number of research firms recently commented on COTY. BMO Capital Markets raised their price objective on shares of Coty from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, February 9th. JPMorgan Chase raised their price objective on shares of Coty from $15.00 to $17.00 and gave the company an “underweight” rating in a research note on Monday, February 12th. Citigroup raised their price objective on shares of Coty from $21.00 to $23.00 and gave the company a “buy” rating in a research note on Friday, February 9th. Barclays set a $20.00 price objective on shares of Coty and gave the company a “hold” rating in a research note on Saturday, February 10th. Finally, Stifel Nicolaus reiterated a “buy” rating on shares of Coty in a research note on Friday, February 9th. Five analysts have rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $19.71.
No comments:
Post a Comment